Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 4, 2018

Primary Completion Date

November 30, 2020

Study Completion Date

December 15, 2026

Conditions
ALL, Adult
Interventions
DRUG

Blinatumomab

prephase and consolidation (I and II)

Trial Locations (18)

Unknown

BE-Antwerpen Edegem-UZA, Antwerp

BE-Antwerpen-ZNASTUIVENBERG, Antwerp

BE-Brugge-AZBRUGGE, Bruges

BE-Gent-UZGENT, Ghent

BE-Leuven-UZLEUVEN, Leuven

BE-Roeselare-AZDELTA, Roeselare

NL-Amersfoort-MEANDERMC, Amersfoort

NL-Amsterdam-AMC, Amsterdam

NL-Amsterdam-VUMC, Amsterdam

NL-Enschede-MST, Enschede

NL-Groningen-UMCG, Groningen

NL-Leiden-LUMC, Leiden

NL-Maastricht-MUMC, Maastricht

NL-Nieuwegein-ANTONIUS, Nieuwegein

NL-Rotterdam-ERASMUSMC, Rotterdam

NL-Den Haag-HAGA, The Hague

NL-Utrecht-UMCUTRECHT, Utrecht

NL-Zwolle-ISALA, Zwolle

All Listed Sponsors
lead

Stichting Hemato-Oncologie voor Volwassenen Nederland

OTHER

NCT03541083 - Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. | Biotech Hunter | Biotech Hunter